Spring Bank’s HBV therapy on hold after signs of liver damage

Spring Bank’s revelation of liver toxicity in chronic HBV patients treated with inarigivir soproxil in a Phase IIb trial sent the company’s shares down 67% Thursday; however, the readout doesn’t necessarily mean that immuno-oncology therapies with the same mechanism will

Read the full 405 word article

How to gain access

Continue reading with a
two-week free trial.